6/12
02:06 am
rytm
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade) [Seeking Alpha]
Medium
Report
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade) [Seeking Alpha]
6/11
04:01 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Medium
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
6/3
04:19 pm
rytm
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 [Yahoo! Finance]
6/3
04:02 pm
rytm
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
Low
Report
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
6/3
08:02 am
rytm
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
Medium
Report
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
5/25
08:43 am
rytm
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week [Yahoo! Finance]
Medium
Report
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week [Yahoo! Finance]
5/22
04:11 am
rytm
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome [Yahoo! Finance]
5/22
04:00 am
rytm
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
Low
Report
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ?IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
5/9
04:12 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants [Yahoo! Finance]
5/9
04:01 pm
rytm
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Low
Report
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
5/8
01:45 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $80.00 to $79.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $80.00 to $79.00. They now have a "buy" rating on the stock.
5/8
10:59 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/8
07:04 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
5/8
07:04 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.
5/7
02:22 pm
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.
5/7
07:16 am
rytm
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
High
Report
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
5/7
07:00 am
rytm
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
High
Report
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
5/6
08:13 am
rytm
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting [Yahoo! Finance]
5/6
08:00 am
rytm
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
Low
Report
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
4/30
12:11 pm
rytm
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline [Yahoo! Finance]
Medium
Report
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/29
06:30 pm
rytm
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
Medium
Report
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
4/26
08:11 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Medium
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
4/24
04:01 pm
rytm
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Medium
Report
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
4/18
07:55 pm
rytm
Cramer's Lighting Round: Sell Aspen Aerogels [CNBC]
Low
Report
Cramer's Lighting Round: Sell Aspen Aerogels [CNBC]
4/18
09:00 am
rytm
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Wells Fargo & Company from $53.00 to $52.00. They now have an "overweight" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Wells Fargo & Company from $53.00 to $52.00. They now have an "overweight" rating on the stock.